cross-posted from : https://lemmy.zip/post/63690202

The UK's Medicines and Healthcare products Regulatory Agency will accept more data from clinical trials in China to accelerate drug approvals.

The regulator plans to set out a strategy later this year, as it wants to leverage the depth of research coming out of China at an ever-increasing rate.

“It’s got to a stage where Western countries like ourselves can no longer have a strategy of not accepting Chinese data — particularly pre-clinical data — to initiate clinical trials here, because what we will end up doing is closing ourselves off to some of the most promising innovative drug development,” Lawrence Tallon, chief executive officer at the MHRA, said in an interview.